Incyte JAK1 inhibitor shines in phase 2 trial

11 Mar 2024
www.pharmamanufacturing.com
Clinical ResultPhase 2Drug ApprovalPhase 3ASCO
Incyte recently revealed positive outcomes from its phase 2 trial of povorcitinib, an oral JAK1 inhibitor, in treating prurigo nodularis (PN), a chronic skin condition characterized by intense itching and the formation of nodules.
The findings, presented at the American Academy of Dermatology Annual Meeting, demonstrated that povorcitinib significantly improved itch relief across various dosage groups compared to a placebo, meeting both primary and secondary study endpoints.
Notably, patients treated with the drug showed a marked improvement in itch reduction and skin condition after just four weeks of treatment, signaling a potential breakthrough for individuals grappling with the persistent and often debilitating symptoms of PN.
Povorcitinib is also being tested in advanced phase 3 trials for skin conditions hidradenitis suppurativa and vitiligo and is in ongoing phase 2 trials for PN, asthma, and a type of hives known as chronic spontaneous urticaria.
Two years ago, the FDA approved Incyte’s JAK inhibitorJAK inhibitor cream, Opzelura, for the topical treatment of nonsegmental vitiligo in patients aged 12 and older. This drug became the first and only FDA-approved product for repigmentation in patients with this condition.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.